Biomm S.A. (BVMF: BIOM3)

Market Cap	979.22M
Revenue (ttm)	122.91M
Net Income (ttm)	-72.70M
Shares Out	126.84M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,500
Open	7.52
Previous Close	7.52
Day's Range	7.22 - 7.52
52-Week Range	5.00 - 21.20
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 25, 2025

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 130
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIOM3

Financial Performance

In 2023, Biomm's revenue was 118.19 million, an increase of 12.62% compared to the previous year's 104.95 million. Losses were -81.14 million, -12.34% less than in 2022.